NCCN Task Force report: Adjuvant therapy for breast cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 4, Issue SUPPL. 1, 2006, Pages

  Carlson, Robert W ^a   Brown, Elizabeth ^a   Burstein, Harold J ^a   Gradishar, William J ^a   Hudis, Clifford A ^a   Loprinzi, Charles ^a   Mamounas, Eleftherios Paul ^a   Perez, Edith A ^a   Pritchard, Kathleen ^a   Ravdin, Peter ^a   Recht, Abram ^a   Somlo, George ^a   Theriault, Richard L ^a   Winer, Eric P ^a   Wolff, Antonio C ^a  

^a NONE

Author keywords

Adjuvant therapy; Aromatase inhibitors; Breast cancer; ER+; Estrogen receptors; Gene expression profiling; HER2; Hormone therapy; NCCN Clinical Practice Guidelines in Oncology; Prognostic factors; Risk of recurrence; Taxanes

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; FOLINIC ACID; LETROZOLE; METHOTREXATE; TAMOXIFEN; TRASTUZUMAB; TUMOR MARKER; ANTINEOPLASTIC AGENT;

ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG INHIBITION; DRUG MECHANISM; DRUG MIXTURE; DRUG TOLERABILITY; GENE OVEREXPRESSION; HORMONAL THERAPY; HORMONE SYNTHESIS; HUMAN; IMMUNOHISTOCHEMISTRY; META ANALYSIS; MINIMAL RESIDUAL DISEASE; PATIENT CARE; POLYMERASE CHAIN REACTION; POSTMENOPAUSE; PRACTICE GUIDELINE; PROGNOSIS; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ADVISORY COMMITTEE; AGED; BREAST TUMOR; COMPARATIVE STUDY; FEMALE; MASTECTOMY; METHODOLOGY; MIDDLE AGED; MORTALITY; RADIATION DOSE; REVIEW; RISK ASSESSMENT; SURVIVAL;

ADULT; ADVISORY COMMITTEES; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MASTECTOMY; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 33645729721     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: None     Document Type: Article

References (96)

1. Carlson RW, Goldstein LJ, Gradishar WR, et al. NCCN Breast Cancer Practice Guidelines. Oncology 1996;10[suppl]:47-75.
2. Carlson RW, Anderson BO, Burstein HJ, et al. NCCN Breast Cancer Practice Guidelines in Oncology, v 2.2006; 2006. Available at www.nccn.org. Accessed February 2006.
3. Carlson RW, Anderson BO, Burstein HJ, et al. Breast cancer: Clinical Practice Guidelines in Oncology. J Natl Compr Cane Netw 2005;3:238-289.
4. Winn RJ, McClure J. The NCCN Clinical Practice Guidelines in Oncology: a primer for users. J Natl Compr Cancer Netw 2003;1:5-13.
5. Hilsenbeck SG, Ravdin PM, de Moor CA, et al. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 1998;52:227-237.
6. Margoleses RG, Hortobagyi GN, Bucholz TA. Neoplasms of the breast. In: Kufe DW, Pollock RE, Weichselbaum RR, et al., eds. Cancer Medicine, 6th ed. Hamilton, Ontario, Canada: American Cancer Society and B.C. Decker; 2003:1892.
7. Elkin HB, Hudis C, Begg CB, Schrag D. The effect of changes in tumor size on breast carcinoma survival in the US: 1975-1999. Cancer 2005;104:1149-1157.
8. Gonzalez-Angulo AM, Hanrahan EO, Giordano SH, et al. Survival of patients with breast cancer tumors 1 cm or less: analysis of the Surveillance, Epidemiology and End Results (SEER) Registry [abstract]. Proc ASCO 2005. Abstract #656.
9. Hellman, S, Harris JR. Diseases of the Breast, 2nd ed. Philadelphia: Lippincott Williams & Williams; 2000:407.
10. Hortobagyi GN, Kau S-W, Buzdar AU, et al. What is the prognosis of patients with operable breast cancer (BC) five years after diagnosis? J Clin Oncol 2004;22[suppl]:585.
11. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717.
12. Diab SG, Clark GM, Osborne CK, et al. Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol 1999;17:1442-1448.
13. Pinder SE, Ellis IO, Galea M, et al. Pathological prognostic factors in breast cancer. III: Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopathology 1994;24:41-47.
14. Slade MJ, Singh A, Smith BM, et al. Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: results at 4 years. Int J Cancer 2005;114:94-100.
15. Weinschenker P, Soares HP, Clark O, et al. Immunocytochemical detection of epithelial cells in the bone marrow of primary breast cancer patients: a meta-analysis. Breast Cancer Res Treat 2004;87:215-224.
16. van't Veer LJ, Dai H, van de Vijver MJ. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-536.
17. van de Vijver MJ, He YD, Van't Veer LJ. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
18. Cobleigh MA, Bitterman P, Baker J, et al. Tumor gene expression predicts distant disease-free survival (DDFS) in breast cancer patients with 10 or more positive nodes: High throughput RT-PCR assay of paraffin-embedded tumor tissues [abstract]. Proc Am Soc Clin Oncol 2003:850.
19. Esteban J, Baker J, Cronin M, et al. Tumor gene expression and prognosis in breast cancer: Multi-gene RT-PCR assay of paraffin-embedded tissue [abstract]. Proc Am Soc Clin Oncol 2003;22:850.
20. Paik S, Shak S, Tang G, et al. Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients: NSABP studies B-20 and B-14 [abstract]. Breast Cancer Res Treat 2003;82:A16.
21. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node negative breast cancer. N Engl J Med 2004;351:2817-2826.
22. Habel LA, Quesenbery CP, Jacobs M, et al. Gene expression and breast cancer mortality in Northern California Kaiser Permanente patients; a large population based case control study [abstract]. 2005 ASCO Annual Meeting, Abstract 603.
23. th annual St. Gallen conference, January 28, 2005, St. Gallen, Switzerland.
24. Gianni L, Zambetti M, Clark K, et al. Gene expression profiles of paraffin-embedded core biopsy tissue predict response to chemotherapy in patients with locally advanced breast cancer. J Clin Oncol 2004;22[suppl]:501.
25. Paik S, Shak S, Tang G, et al. Expression of the 21 genes in the recurrence score assay and prediction of clinical benefit from tamoxifen in NSABP study B-14 and chemotherapy in NSABP study B-20 [abstract]. Presented at the 2004 San Antonio Breast Cancer Symposium, December 8-11, 2004, San Antonio, Texas. Abstract #24.
26. Dellapasqua S, Colleoni M, Gelber RD, Goldhirsch A. Adjuvant endocrine therapy for premenopausal women with early breast cancer. J Clin Oncol 2005;23:1736-1750.
27. Extermann M, Balducci L, Lyman GH. What threshold for adjuvant therapy in older breast cancer patients? J Clin Oncol 2000;18:1709-1717.
28. Aebi S, Gelber S, Castiglione-Gertsch M, et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 2000;355:1869-1874.
29. Goldhirsch A, Gelber RD, Yothers G, et al. Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr 2001:44-51.
30. Fisher B, Jeong JH, Dignam J, et al. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr 2001;30:62-66.
31. Muss HB, Woolf S, Berry D, et al. Adjuvant chemotherapy in older and younger women with lymph node positive breast cancer. JAMA 2005;293:1073-1081.
32. Kornblith AB, Kemeny M, Peterson BL, et al. Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials. Cancer 2002;95:989-996.
33. Kemeny MM, Peterson BL, Kornblith AB, et al. Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 2003;21:2268-2275.
34. Siminoff LA, Zhang A, Colabianchi N, et al. Factors that predict the referral of breast cancer patients onto clinical trials by their surgeons and medical oncologists. J Clin Oncol 2000;18:1203-1211.
35. International Breast Cancer Study Group. Endocrine responsiveness and tailoring adjuvant therapy for post menopausal lymph node negative breast cancer. A randomized trial. J Natl Cancer Inst 2002;94:1054-1065.
36. Fisher B, Jeong JH, Bryant J, et al. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 2004;364:858-868.
37. Albain K, Barlow W, O'Malley F, et al. Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: Mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814) [abstract]. Presented at the 2004 San Antonio Breast Cancer Symposium, December 8-11, 2004, San Antonio, Texas. Abstract #37.
38. Gennari R, Curigliano G, Rotmensz N, et al. Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopausal patients. Cancer 2004;101:1302-1310.
39. Fried et al. Decision modeling for the adjuvant treatment of older patients with breast cancer. J Gerontol Biol Sci Med Sci 2001;56:M146-M156.
40. Arias E. United States life tables, 2002. Natl Vital Stat Rep 2004;53:1-38.
41. Loprinzi CL, Ravdin PM, de Laurentiis M, Novotny P. Do American oncologists know how to use prognostic variables for patients with newly diagnosed primary breast cancer? J Clin Oncol 1994;12:1422-1426.
42. Ravdin PM. A computer-based program to assist in adjuvant therapy decision for individual breast cancer patients. Bull Cancer 1995;82[suppl 5]:561S-564S.
43. Ravdin PM. A computer program to assist in making breast cancer adjuvant therapy decisions. Semin Oncol 1996;23[suppl 2]:43-50.
44. Loprinzi CL, Thome SD. Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol 2001;19:972-979.
45. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer J Clin Oncol 2001;19:980-991.
46. Olivotto IA, Bajdik CD, Ravdin PM, et al. population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005;23:2716-2725.
47. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001;93:684-690.
48. Stewart HJ, Prescott RJ, Forrest AP. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst 2001;93:456-462.
49. Tormey DC, Gray R, Falkson HC. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer Eastern Cooperative Oncology Group. J Natl Cancer Inst 1996;88:1828-1833.
50. Boccardo F, Rubagotti A, Amoroso D, et al. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol 2000;18:2718-2727.
51. Jakesz R, Hausmaninger H, Kubista E, et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate and fluorouracil: Evidence for the superiority of treatment with endocrine blockage in premenopausal patients with hormone responsive breast cancer. J Clin Oncol 2002;20:4621-4627.
52. Danforth DN Jr. How subsequent pregnancy affects outcome in women with a prior breast cancer. Oncology 1991;5:23-30; discussion, 30-21, 35.
53. Sankila R, Heinavaara S, Hakulinen T. Survival of breast cancer patients after subsequent term pregnancy: "healthy mother effect". Am J Obstet Gynecol 1994;170:818-823.
54. Jonat W, Kauffmann M, Sauerbrei W, et al. Goserelin versus cyclophosphamide, methotrexate and fluorouracil as adjuvant therapy in premenopausal patients with node positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 2002;20:4628-4635.
55. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-62.
56. Thurlimann BJ, Keshaviah A, Mouridsen H, et al. Randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer [abstract]. J Clin Oncol 2005;23[suppl]:6S. Abstract #511.
57. Dowsett M, Cuzick J, Wale C, et al, on behalf of the ATAC Trialists' Group. Retrospective analysis of time to recurrence in the ATAC Trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 2005;23:7512-7517.
58. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-1092.
59. Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005;23:5138-5147.
60. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455-462.
61. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262-1271.
62. Goss PE, Ingle JN, Martino S, et al. Updated analysis of the NCIC CTG MA.17 randomized placebo controlled trial of letrozole after five years of tamoxifen in postmenopausal women with early stage breast cancer. J Clin Oncol 2004;22[suppl]:847.
63. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitor as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol 2005;23:619-623.
64. Nissen-Meyer R, Kjellgren K, Mansson B. Preliminary report from the Scandinavian adjuvant chemotherapy study group. Cancer Chemother Rep 1971;55:561-566.
65. Nissen-Meyer R, Kjellgren K, Mansson B. Adjuvant Chemotherapy in Breast Cancer. Recent Results in Cancer Research. Berlin-Heidelberg: Springer-Verlag; 1982:142-218.
66. Fisher B, Carbone P, Economou SG, et al. 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer: a report of early findings. N Engl J Med 1975;292:117-122.
67. Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976;294:405-410.
68. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 1998;352:930-942.
69. Poole CJ, Earl HM, Dunn JA. NEAT (National Epirubicin Adjuvant Trial) and SCTBG BR9601 (Scottish Cancer Trials Breast Group) phase III adjuvant breast trials show a significant relapse-free and overall survival advantage for sequential ECMF [abstract]. Proc Am Soc Clin Oncol 2003;22:4. Abstract #13.
70. Levine MN, Pritchard KI, Bramwell VH, et al. Randomized trail comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institue of Canada Clinical Trials Group Trial MA5. J Clin Oncol 2005;23:5166-5170.
71. Thor AD, Liu S, Edgerton S, et al. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. J Clin Oncol 2000;18:3230-3239.
72. Learn PA, Yeh IT, McNutt M, et al. HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma. Cancer 2005; 103:2252-2260.
73. Paik S, Bryant J, Tan-Chiu E, et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 2000;92:1991-1998.
74. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672.
75. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684.
76. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
77. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin induced congestive heart failure. Ann Intern Med 1979;91:710-717.
78. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 2003;97:2869-2879.
79. Crump M, Tu D, Shepherd L, et al. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003;21:3066-3071.
80. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21:976-983.
81. Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005;23:3686-3696.
82. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352:2302-2313.
83. Roché H, Fumoleau P, Spielmann M, et al. Five years analysis of the PACS 01 trial: 6 cycles of FEC100 vs. 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer [abstract]. Breast Cancer Res Treat, 88[suppl 1]. Abstract #27.
84. Bear HD, Anderson S, Smith RE, et al. A randomized trial comparing preoperative (preop) doxorubicin/cyclophosphamide (AC) to preop AC followed by preop docetaxel (T) and to preop AC followed by postoperative (postop) T in patients (pts) with operable carcinoma of the breast: results of NSABP B-27 [abstract]. SABCS 2004. Abstract #26.
85. Sparano JA, Wang M, Martino S, et al. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: results of North American Breast Cancer Intergroup Trial E1199. Presented at the San Antonio Breast Cancer Symposium; San Antonio: December 8, 2005 [abstract 48].
86. Perez EA. Special education session. Presented at ASCO, 2005.
87. Romond EH, Perez EA, Bryant J, et al. Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER-2 positive operable breast cancer: combined analysis of NS-ABP B-31 and NCCTG N9831. Presented at ASCO, 2005. Available at: http://www.asco.org/ac/1,1003,_12-002511-00_18-0034-00_19-005817-00_21-001,00. asp. Accessed October 20, 2005.
88. Perez EH, Suman VJ, Davidson N. NCCTG N8931: May 2005 update. Presented at ASCO, 2005. Available at: http://www.asco.org/ac/1,1003,_12-002511-00_18- 0034-00_19-005815-00_21-001,00.asp. Accessed October 20, 2005.
89. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:3676-3685.
90. Vinh-Hung V, Royce M, Verschraegen C, et al. Age-patterns of mortality in early breast cancer: A graphical presentation [abstract]. Presented at the 2004 San Antonio Breast Cancer Symposium, December 8-11, 2004, San Antonio, Texas. Abstract #5042.
91. Colleoni M, Li S, Gelber RD, Coates AS, Timing of CMF chemotherapy in combination with tamoxiten in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor. Ann Oncol 2005;16:716-725.
92. Bellon JR, Come SE, Gelman RS, et al. Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial. J Clin Oncol 2005;23:1934-1940.
93. Hartsell WF, Recine DC, Griem KL, Murthy AK. Delaying the initiation of intact breast irradiation in patients with lymph node positive breast cancer increases the risk of local recurrence. Cancer 1995;76:2497-2503.
94. Calais G, Serin D, Fourquet A, et al. Randomized study comparing adjuvant radiotherapy (RT) with concomitant chemotherapy (CT) versus sequential treatment after conservative surgery for patients with stages I and II breast carcinoma. Int J Radiat Oncol Biol Phys 2002;2(suppl):57-58.
95. Bellon JR, Shulman LN, Come SE, et al. A prospective study of concurrent cyclophosphamide/methotrexate/5-fluorouracil and reduce-dose radiotherapy in patients with early-stage breast carcinoma. Cancer 2004;100:1358-1364.
96. Sartor CI, Peterson BL, Woolf S, et al. Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: Cancer and Leukemia Group B 9344. J Clin Oncol 2005;23:30-40.